Slovenia Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Slovenia Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Slovenia Pharmaceuticals & Healthcare Report
Product Price
$1,345.00

BMI View: Slovenia's healthcare system is relatively developed and effective, particularly when compared with other markets in Central and Eastern Europe. In addition, Slovenia's disease profile is an attractive one for innovative drugmakers , as non-communicable diseases - cancer and cardiovascular diseases in particular - pose a great burden. On the other hand, the country's small population and market size may limit major investments from multinationals.

Headline Expenditure Projections

  • Pharmaceuticals: EUR671mn (USD745mn) in 2015 to EUR673mn (USD720mn) in 2016; 0.3% in local currency terms and -3.3% in US dollar terms. Forecasts revised upwards compared to previous quarter.

  • Healthcare: EUR3.45bn (USD3.83bn) in 2015 to EUR3.56bn (USD3.80bn) in 2016; 3.1% in local currency terms and -0.6% in US dollar terms. Forecasts increased slightly relative to previous quarter .

Headline Pharmaceuticals & Healthcare Forecasts (Slovenia 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: National sources, WHO, BMI
Pharmaceutical sales, USDbn 0.896 0.745 0.720 0.716 0.710 0.717 0.743
Pharmaceutical sales, % of GDP 1.81 1.74 1.70 1.67 1.63 1.60 1.59
Pharmaceutical sales, % of health expenditure 20.1 19.5 18.9 18.5 18.3 18.1 18.1
Health spending, USDbn 4.453 3.828 3.804 3.858 3.883 3.953 4.111

BMI Risk/Reward Index

Slovenia's Risk/Rewards score is limited by a meagre Rewards score - a reflection of the small size of the market due to the country's small population, as well as its scant growth prospects. Slovenia scores 49.3 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q117, decreasing from 9th to 12th place compared to the previous quarter. Slovenia scores below the average for the region, which is 51.1.

Latest Updates

  • In June 2016, Ales Delakorda of the Institute of Macroeconomic Analysis and Development (IMAD) voiced concerns that Slovenia is among countries with the highest risks of shortfall in public finances due to its ageing population. The country will require comprehensive changes to address this issue.

  • According to the European Commission's long-term estimates, Slovenia's expenditure on pensions, healthcare and long-term care will rise from 18.9% in 2013 to a quarter of the country's GDP by 2060, if left without intervention. (The Slovenia Times)

  • As announced in August 2016, the Slovenian Chamber of Pharmacies has estimated that despite the fragile economy, more than EUR50mn (USD53mn) was spent on over-the-counter drugs last year, extending growth seen since 2010. The biggest rise was recorded in weight-loss drugs, cough and cold medications as well as pain killers. The Chamber of Pharmacies has estimated that private expenditure on pharmaceuticals in Slovenia will continue to increase, primarily because of the ageing population and prevailing unhealthy lifestyle.

BMI Economic View

As the government coalition reaches the halfway point of its four-year term, its track record so far has been largely positive in terms of restoring political stability and institutional order following the successive government collapses in the 2011-2014 period. It has overseen an impressive reduction in the budget deficit, a return to solid growth and, more recently, a meaningful improvement in the labour market.

BMI Political View

The loss of public support poses a threat to the three-party governing coalition, one that is not a major concern now but will grow as we move closer to the 2018 elections and parties begin to court voters. With this in mind, we expect the risks to policymaking to gradually increase starting next year, making the coming quarters crucial in terms of enacting badly needed reforms in sensitive areas like pensions and the recovering banking sector.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Slovenia 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovenia 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2012-2020)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovenia 2012-2020)
17
Prescription Drug Market Forecast
18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovenia 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovenia 2012-2020)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovenia 2012-2020)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovenia 2012-2020)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Slovenia 2014-2020)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovenia 2014-2020)
30
Industry Risk/Reward Index
31
Central And Eastern Europe Risk/Reward Index - Q3 2016
31
Slovenia Risk/Reward Index
37
Rewards
37
Risks
37
Regulatory Review
39
Intellectual Property Issues
40
Pricing Regime
40
Reimbursement Regime
42
Market Overview
44
Healthcare Sector
45
Table: Healthcare Resources (Slovenia 2010-2015)
49
Table: Healthcare Personnel (Slovenia 2010-2015)
49
Table: Healthcare Activity (Slovenia 2010-2015)
50
Research & Development
50
Clinical Trials
50
Epidemiology
51
Competitive Landscape
54
Research-Based Industry
54
Table: Table: Multinational Market Activity
54
Generic Drugmakers
55
Company Profile
58
Krka
58
Lek (Novartis/Sandoz)
63
Demographic Forecast
67
Table: Population Headline Indicators (Slovenia 1990-2025)
68
Table: Key Population Ratios (Slovenia 1990-2025)
68
Table: Urban/Rural Population & Life Expectancy (Slovenia 1990-2025)
69
Table: Population By Age Group (Slovenia 1990-2025)
69
Table: Population By Age Group % (Slovenia 1990-2025)
70
Glossary
72
Methodology
74
Pharmaceutical Expenditure Forecast Model
74
Healthcare Expenditure Forecast Model
74
Notes On Methodology
75
Risk/Reward Index Methodology
76
Index Overview
77
Table: Pharmaceutical Risk/Reward Index Indicators
77
Indicator Weightings
78

The Slovenia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Slovenia, to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.